Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
ADHD
Interventions
DRUG

Placebo

Placebo was administered once daily

DRUG

200mg SPN-812

200mg SPN-812 was administered once daily and compared to placebo

DRUG

400mg SPN-812

400mg SPN-812 was administered once daily and compared to placebo

Trial Locations (12)

10029

Icahn School of Medicine at Mount Sinai, New York

14618

Finger Lakes Clinical Research, Rochester

32217

Clinical Neuroscience Solutions, Inc, Jacksonville

33012

Indago Research & Health Center, Inc., Hialeah

33155

Miami Clinical Research, Miami

36303

Harmonex Neuroscience Research, Dothan

38119

Clinical Neuroscience Solutions, Inc., Memphis

76014

Texas Physicians Medical Research Group, Arlington

77098

Houston Clinical Trials, Houston

77381

Family Psychiatry of the Woodlands, The Woodlands

83642

Advanced Clinical Research, Meridian

92868

Neuropsychiatric Research Center of Orange County, Orange

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03247517 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD | Biotech Hunter | Biotech Hunter